A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(9 sites)

France

Neurology Department, CHU d'Angers, Angers

Genetics Department, CHU de Bordeaux, Bordeaux

Neurology and Gentics Department, CHU de Dijon, Dijon

Neurology Department, Hôpital Pierre Wertheimer Hospital, Lyon

Neurology Department, Gui De Chauliac Hospital, Montpellier

Genetics Department, Pitié-Salpêtrière University Hospital, Paris

Genetics Department, CHU de Rouen, Rouen

Neurology Department, CHRU de Strasbourg, Strasbourg

Neurology Department, CHU de Toulouse, Toulouse